Expect to See Resmetirom for NASH on Home Med Lists

July 2024

Resmetirom (Rezdiffra) will be the first med approved for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis in adults.

About 5% of adults in the US have NASH...liver fat and inflammation that can progress to fibrosis and cirrhosis.

You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH)...to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote